GlaxoSmithKline Pharmaceuticals Q1 Results FY27: PAT at Rs 237 Cr for June 2026 Quarter

The GlaxoSmithKline Pharmaceuticals Q1 results FY27 show consolidated revenue of Rs 938 Cr for the quarter ended 30 June 2026, +16.55% year on year from Rs 805 Cr in Q1 FY26, as GlaxoSmithKline Pharmaceuticals reported its numbers on 4 August 2026. GlaxoSmithKline Pharmaceuticals posted pat of Rs 237 Cr for the quarter, against Rs 205 Cr in Q1 FY26, a change of +15.69%. Shares traded around Rs 2,631.2 on the NSE, down 1.17% on the day.

The June 2026 quarter played out against a broadly stable macro backdrop, contained inflation, a supportive monsoon outlook, and resilient domestic consumption, though global uncertainty around tariffs and commodity prices kept sector-level variability elevated. Against that backdrop, the GlaxoSmithKline Pharmaceuticals Q1 results FY27 give investors the first hard data point for FY27. This article breaks down what happened at the revenue, gross profit, and net profit line, what the numbers mean for the full year, and what questions investors should be asking before making any portfolio decision.

Click Here – Get Free Investment Predictions

GlaxoSmithKline Pharmaceuticals Q1 results FY27 Financial Highlights

All figures are consolidated numbers in Rs Crore as reported by GlaxoSmithKline Pharmaceuticals for Q1 FY27 (April to June 2026). The table compares them against the same quarter in FY26.

Metric	Q1 FY27 (Jun 2026)	Q1 FY26 (Jun 2025)	YoY Change
Revenue	Rs 938 Cr	Rs 805 Cr	+16.55%
Gross Profit	Rs 279 Cr	Rs 235 Cr	+18.66%
Gross Profit Margin	29.7%	29.2%	+0.6 pts
Net Profit (PAT)	Rs 237 Cr	Rs 205 Cr	+15.69%
Net Profit Margin	25.3%	25.5%	-0.2 pts

GlaxoSmithKline Pharmaceuticals Q1 results FY27 Performance Analysis

GlaxoSmithKline Pharmaceuticals delivered steady topline progress this quarter. Revenue grew +16.55% year on year to Rs 938 Cr, against Rs 805 Cr in Q1 FY26. The growth is organic and in line with the company's stated ambitions for FY27, suggesting the business is executing broadly on plan.

Gross profit improved faster than revenue. The gross profit came in at Rs 279 Cr (29.7% margin), up +18.66% year on year from Rs 235 Cr. The positive operating jaws confirm that GlaxoSmithKline Pharmaceuticals is converting its topline growth into margin expansion rather than giving it away on costs.

GlaxoSmithKline Pharmaceuticals converted its revenue growth into earnings gains. Net profit (pat) grew +15.69% to Rs 237 Cr from Rs 205 Cr a year earlier. Consistency here over several quarters would support a valuation re-rating.

Check the Univest Screener for Live Data

GlaxoSmithKline Pharmaceuticals Q1 results FY27: Key Business Factors

1. Revenue: What Drove the Quarter

GlaxoSmithKline Pharmaceuticals reported revenue of Rs 938 Cr against Rs 805 Cr in Q1 FY26, a change of +16.55%. Understanding this revenue figure requires context: in the pharmaceuticals sector, volume growth and realisation per unit are both drivers, and the aggregate revenue number is the product of both. Investors tracking GlaxoSmithKline Pharmaceuticals should check the investor presentation or earnings call commentary for the volume-versus-pricing split underlying this quarter's topline.

2. Gross Profit and Margin Trends

Gross margin was broadly stable at 29.7% versus 29.2% in Q1 FY26. Stability in this line is a credible outcome for the pharmaceuticals sector, where raw material and API cost volatility, regulatory approvals and pricing pressure in key markets can move margins sharply quarter to quarter. Sustained gross margin stability gives management a predictable base to work from as it invests in growth for the rest of FY27.

3. Net Profit and Earnings Quality

GlaxoSmithKline Pharmaceuticals posted pat of Rs 237 Cr for the June 2026 quarter, against Rs 205 Cr in Q1 FY26, a change of +15.69%. This bottom line figure is what drives earnings per share and, ultimately, the P/E multiple at which the stock trades. Analysts will now update their FY27 EPS estimates using this Q1 run rate, adjusted for any seasonal factors and guidance management provides on the earnings call.

GlaxoSmithKline Pharmaceuticals Q1 results FY27 vs Analyst Expectations

Whether the GlaxoSmithKline Pharmaceuticals Q1 results FY27 met, beat, or missed analyst forecasts will determine how quickly institutional investors reposition their holdings.

Analyst estimates for the GlaxoSmithKline Pharmaceuticals Q1 results FY27 varied ahead of the announcement. The actual revenue of Rs 938 Cr and PAT of Rs 237 Cr now set the benchmark against which FY27 consensus estimates will be revised. When a company beats on both revenue and profit, the stock typically sees buying in the first post-result session. A miss on both tends to trigger selling and downgrades. A mixed print stays range-bound until the earnings call provides clarity. Investors tracking GlaxoSmithKline Pharmaceuticals should check live analyst verdict updates on the Univest Screener alongside the stock price movement to contextualise the post-result market reaction.

GlaxoSmithKline Pharmaceuticals Dividend Update

No specific dividend announcement was confirmed as part of the GlaxoSmithKline Pharmaceuticals Q1 results FY27 snapshot. Most companies declare dividends at the annual board meeting rather than with quarterly results. Investors tracking GlaxoSmithKline Pharmaceuticals for its dividend yield should check the official NSE or BSE exchange filing, or the Univest Screener, for the latest record date and payout details.

GlaxoSmithKline Pharmaceuticals Outlook After Q1 results FY27

The GlaxoSmithKline Pharmaceuticals Q1 results FY27 establish the Q1 FY27 baseline for revenue at Rs 938 Cr and PAT at Rs 237 Cr. Whether FY27 ends up as a year of acceleration depends on two variables: whether the growth in revenue sustains through Q2 to Q4, and whether margin trends improve, stabilise, or deteriorate relative to this quarter's gross profit margin of 29.7% . Management guidance on the earnings call will be the single most important datapoint for updating FY27 forecasts. Investors should also track macroeconomic inputs relevant to the pharmaceuticals sector through the rest of the year.

Investors tracking GlaxoSmithKline Pharmaceuticals after the Q1 FY27 numbers should focus on three things heading into Q2 FY27: whether the growth in revenue sustains, whether the improvement trend in profit continues without the help of one-off items, and whether management's guidance for FY27 holds. A results conference call or investor presentation, if scheduled, will be the primary opportunity for management to address these questions.

Should You Buy GlaxoSmithKline Pharmaceuticals After the Q1 results FY27?

The question most investors ask after any quarterly result is whether it changes the investment case. The GlaxoSmithKline Pharmaceuticals Q1 results FY27 show revenue of Rs 938 Cr, gross profit of Rs 279 Cr, and PAT of Rs 237 Cr. Whether these numbers justify buying, holding, or selling depends on the price the stock is trading at (Rs 2,631.2 at the time of this result), the FY27 consensus earnings estimate, and whether this Q1 run rate is sustainable for the remaining three quarters. Investors should check the P/E, P/B, and EV/EBITDA multiples on the Univest Screener against sector peers before deciding. This article is for educational purposes only and does not constitute investment advice. Please consult a SEBI-registered investment advisor before making any investment decision.

GlaxoSmithKline Pharmaceuticals Share Price After the Q1 results FY27

GlaxoSmithKline Pharmaceuticals shares traded at Rs 2,631.2 on the NSE, down 1.17% on the day the GlaxoSmithKline Pharmaceuticals Q1 results FY27 were in focus. Post-result price moves are often driven by event-driven traders who have built positions ahead of the result and unwind them regardless of outcome. Investors should look past the first-session move and focus on whether the fundamental trend in revenue and earnings has changed. The 52 week high, 52 week low, and technical support levels for GlaxoSmithKline Pharmaceuticals are available on the Univest Screener for investors who want to time their entry or exit.

Download the Univest iOS App or Univest Android App to track GlaxoSmithKline Pharmaceuticals live share price and upcoming quarterly results.

Key Risks to Track After the GlaxoSmithKline Pharmaceuticals Q1 results FY27

Investors should weigh these risks carefully before acting on the Q1 data.

1. Sector and Margin Risk

GlaxoSmithKline Pharmaceuticals operates in the pharmaceuticals sector, which is exposed to raw material and API cost volatility, regulatory approvals and pricing pressure in key markets. A reversal of the trends visible in the GlaxoSmithKline Pharmaceuticals Q1 results FY27, particularly on the gross profit margin, could put the full-year FY27 earnings estimate at risk.

2. Single-Quarter vs Trend Risk

A single quarterly result can be distorted by working capital cycles, timing of receivables, or one-off costs and reversals that do not repeat. The GlaxoSmithKline Pharmaceuticals Q1 results FY27 should be read alongside Q2 data before drawing firm conclusions.

3. Macro and External Risk

Macro factors including RBI rate decisions, INR/USD movements, input commodity prices, and rural versus urban demand mix can shift the environment in the pharmaceuticals sector faster than company-level actions can compensate for.

Conclusion

Investors researching the GlaxoSmithKline Pharmaceuticals Q1 results FY27 will find the key numbers, revenue, gross profit, and net profit, summarised in the table above and analysed in each section of this article.

The GlaxoSmithKline Pharmaceuticals Q1 results FY27 show consolidated revenue of Rs 938 Cr (+16.55% year on year) and PAT of Rs 237 Cr (versus Rs 205 Cr in Q1 FY26). Gross profit came in at Rs 279 Cr at a margin of 29.7%, improving from Rs 235 Cr a year earlier. Revenue growth and a stronger bottom line were the two key themes of the quarter. Investors tracking GlaxoSmithKline Pharmaceuticals should use the GlaxoSmithKline Pharmaceuticals Q1 results FY27 as the baseline and watch Q2 FY27 results, due around October 2026, as the first confirmation of whether these trends are durable. Always consult a SEBI-registered advisor before acting on any quarterly result.

Frequently Asked Questions on GlaxoSmithKline Pharmaceuticals Q1 results FY27

What were the GlaxoSmithKline Pharmaceuticals Q1 results FY27?

Ans. GlaxoSmithKline Pharmaceuticals reported revenue of Rs 938 Cr (+16.55% YoY) and PAT of Rs 237 Cr for Q1 FY27 (quarter ended 30 June 2026), against Rs 205 Cr in Q1 FY26.

What is the PAT in the GlaxoSmithKline Pharmaceuticals Q1 results FY27?

Ans. PAT in the GlaxoSmithKline Pharmaceuticals Q1 results FY27 stood at Rs 237 Cr, compared with Rs 205 Cr in Q1 FY26, a change of +15.69%.

What was the revenue in the GlaxoSmithKline Pharmaceuticals Q1 results FY27?

Ans. Revenue in the GlaxoSmithKline Pharmaceuticals Q1 results FY27 was Rs 938 Cr, a change of +16.55% from Rs 805 Cr in Q1 FY26.

What was the gross profit in the GlaxoSmithKline Pharmaceuticals Q1 results FY27?

Ans. Gross profit in the GlaxoSmithKline Pharmaceuticals Q1 results FY27 was Rs 279 Cr (29.7% margin), compared with Rs 235 Cr in Q1 FY26, a change of +18.66%.

Did GlaxoSmithKline Pharmaceuticals declare a dividend with the Q1 results FY27?

Ans. No dividend was confirmed as part of the GlaxoSmithKline Pharmaceuticals Q1 results FY27 snapshot. Check the NSE or BSE exchange filing for the latest dividend announcement from GlaxoSmithKline Pharmaceuticals.

What is the outlook for GlaxoSmithKline Pharmaceuticals after Q1 results FY27?

Ans. Following the GlaxoSmithKline Pharmaceuticals Q1 results FY27, analysts will track whether the growth in revenue and improvement in profit continue into Q2 FY27 (September quarter), along with margin trends and management guidance.

Is GlaxoSmithKline Pharmaceuticals a good buy after Q1 results FY27?

Ans. The GlaxoSmithKline Pharmaceuticals Q1 results FY27 show revenue of Rs 938 Cr and PAT of Rs 237 Cr. Investment decisions should be based on valuation relative to earnings trajectory, not a single quarter. Consult a SEBI-registered advisor before investing.